Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2019 | MiST: molecularly targeted therapy for malignant pleural mesothelioma

The British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland, presented exciting updates in mesothelioma. One such update was that of the international umbrella study of Mesothelioma Stratified Therapy (MiST) for malignant pleural mesothelioma. Here, Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, discusses the study, which is targeting the genetics of this disease. Prof. Fennell details the first arm of the MiST study, which will be utilizing the PARP inhibitor rucaparib.